Brief: ANI Pharmaceuticals Q4 Adjusted EPS USD 1 Vs. IBES Estimate USD 0.85
29/02/2024 11:50
Feb 29 (Reuters) - ANI Pharmaceuticals Q4 revenue USD 131.654 million vs. IBES estimate USD 122.2 million. * Q4 net income USD 700 thousand * Q4 operating expenses USD 124.9 million * outlook FY adjusted EPS USD 4.26-4.67 * outlook FY adjusted EBITDA USD 135-145 million
Recent news on ANI Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
ANI Pharmaceuticals Q1 revenue rises 21%, adjusted EPS beats estimates
Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 2.05 Vs. IBES Estimate USD 1.3
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma